• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by AstraZeneca

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
PT027 Recommended by FDA Advisory Committee as New Rescue Treatment for Asthma
November 09, 2022
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
Camizestrant Significantly Improved Progression-free Survival Vs. FASLODEX® (fulvestrant) in SERENA-2 Phase II Trial in Advanced ER-positive Breast Cancer
October 26, 2022
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
Capivasertib plus FASLODEX® (fulvestrant) significantly improved progression-free survival vs. FASLODEX in CAPItello-291 Phase III trial in advanced HR-positive breast cancer
October 26, 2022
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
IMJUDO® (tremelimumab) in Combination With IMFINZI® (durvalumab) Approved in the US for Patients With Unresectable Liver Cancer
October 24, 2022
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
AstraZeneca Announces Winners of Fourth Annual Cancer Community Awards
October 20, 2022
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
AstraZeneca Partners with Jeff Bridges, Kumail Nanjiani, and Emily V. Gordon to Educate the Immunocompromised Community about Added Protection Against COVID-19
September 15, 2022
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
IMFINZI® (durvalumab) plus chemotherapy further improved overall survival benefit in advanced biliary tract cancer in the TOPAZ-1 Phase III trial, reducing the risk of death by 24% in additional follow-up
September 12, 2022
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Continues to Demonstrate Clinically Meaningful Tumor Response in Patients with HER2-mutant Metastatic Non-small Cell Lung Cancer
September 11, 2022
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
IMFINZI® (durvalumab) and tremelimumab with chemotherapy demonstrated sustained survival benefit in metastatic non-small cell lung cancer, nearly doubling the number of patients alive after three years vs. chemotherapy
September 11, 2022
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
TAGRISSO® (osimertinib) demonstrated 5.5-year median disease-free survival in the adjuvant treatment of patients with EGFR-mutated lung cancer
September 11, 2022
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
LYNPARZA® (olaparib) in Combination with Bevacizumab, and as a Monotherapy, Demonstrates Clinically Meaningful Survival Benefit in 1st-Line Advanced Ovarian Cancer Across Two Phase III Trials
September 09, 2022
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
IMFINZI® (durvalumab) Plus Chemotherapy Approved in the US as the First Immunotherapy Regimen for Patients with Advanced Biliary Tract Cancer
September 05, 2022
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
New data show FARXIGA significantly lowers the risk of cardiovascular death in patients with heart failure
August 27, 2022
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
FARXIGA significantly reduced the risk of cardiovascular death or worsening of heart failure in patients with mildly reduced or preserved ejection fraction in DELIVER Phase III trial
August 27, 2022
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
AstraZeneca aims to transform cancer outcomes with new data across industry-leading portfolio at ESMO 2022
August 24, 2022
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
LYNPARZA® (olaparib) in combination with abiraterone granted Priority Review in the US for patients with metastatic castration-resistant prostate cancer
August 16, 2022
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as the first HER2-directed therapy for patients with previously treated HER2-mutant metastatic non-small cell lung cancer
August 12, 2022
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
TAGRISSO® plus savolitinib demonstrated 49% objective response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial
August 08, 2022
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as the first HER2-directed therapy for patients with HER2-low metastatic breast cancer
August 05, 2022
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
CALQUENCE® (acalabrutinib) tablet formulation approved in the US across current indications
August 05, 2022
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patients with HER2-low metastatic breast cancer
July 25, 2022
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
AstraZeneca Shares Data at EASL and ESMO World GI for IMFINZI® (durvalumab) Combinations in Patients With Liver and Biliary Tract Cancers
July 01, 2022
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
PROpel Phase III Trial Positive Results of LYNPARZA® (olaparib) Plus Abiraterone in 1st-line Metastatic Castration-resistant Prostate Cancer Published in New England Journal of Medicine Evidence
June 21, 2022
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
Eplontersen Met Co-Primary and Secondary Endpoints in Interim Analysis of the NEURO-TTRansform Phase III Trial for Hereditary Transthyretin-Mediated Amyloid Polyneuropathy (ATTRv-PN)
June 21, 2022
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Reduced the Risk of Disease Progression or Death by 50% vs. Chemotherapy in Patients with HER2-Low Metastatic Breast Cancer with HR-Positive and HR-Negative Disease
June 05, 2022
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
CALQUENCE Plus Obinutuzumab Demonstrated Sustained Survival Benefit in 1st-line Chronic Lymphocytic Leukemia with 90% of Patients Surviving Five Years in ELEVATE-TN Trial
June 04, 2022
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
First Patients Dosed in IRIS Phase III Trial Evaluating Anifrolumab in Lupus Nephritis
May 27, 2022
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
AstraZeneca aims to transform cancer care with practice-changing data at ASCO 2022
May 23, 2022
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
PT027, a Novel Fixed-Dose Combination of Albuterol and Budesonide, Used as an As-Needed Rescue Medicine, Significantly Reduced the Risk of a Severe Exacerbation Compared to Albuterol by 27% in Patients With Asthma
May 15, 2022
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
FARXIGA met primary endpoint in DELIVER Phase III trial, reducing risk of cardiovascular death or worsening heart failure in patients with preserved ejection fraction
May 05, 2022
From AstraZeneca
Via Business Wire
Tickers AZN
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap